Brief report: severe symptoms of hyperhistaminemia after treatment of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)

Article Abstract:

A 36-year-old Japanese man with acute promyelocytic leukemia suffered an adverse reaction to treatment with tretinoin. Tretinoin is a drug that can be used to treat patients with acute promyelocytic leukemia. The patient was admitted to the hospital with fever and reduced levels of red blood cells, white blood cells and blood platelets. He had been treated for a stomach ulcer three months before admission. A bone marrow biopsy revealed that he was suffering from acute promyelocytic leukemia, and he was treated with oral tretinoin. His temperature returned to normal, and he began to feel better within a week. He developed another fever and flushing 12 days after admission. He developed a rapid heart beat, and went into shock several days later. His stomach ulcer worsened and he developed two more ulcers. Bone marrow smears revealed that he was suffering from an adverse reaction to tretinoin.

Complications and side effects

---

The maturation of differentiation therapy

Article Abstract:

The use of differentiation therapy to treat different types of cancer is still relatively new. Drugs used for differentiation therapy kill or suppress the growth of cancer cells, without harming normal cells. One of the main drawbacks of traditional chemotherapy is that it harms normal tissue. The drugs that have been most effective for differentiation therapy are the retinoids, which include vitamin A, tretinoin and iso-tretinoin. Use of tretinoin was almost discontinued because large doses can damage the central nervous system. In 1988, a research study found that tretinoin was effective in treating patients with acute promyelocytic leukemia. Approximately 80% of patients experience complete remission after treatment with tretinoin. Another research study found that tretinoin impaired the immune system and caused ulcers in a man treated for acute promyelocytic leukemia.

Health aspects, Editorial, Cancer

---

DNA topoisomerase II in therapy-related acute promyelocytic leukemia

Article Abstract:

Acute promyelocytic leukemia (APL) with the t(15;17) translocation that developed after treatment of breast or larnygeal cancer with chemotherapeutic agents that poison topoisomerase II is studied. Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomerase II poisons.

United States, Science & research, Research, Breast cancer, DNA topoisomerase I

Similar abstracts:

• Abstracts: Large-volume paracentesis in treatment of ascites. Antibiotic-induced D-lactic acidosis. Increased osmolal gap in alcoholic ketoacidosis and lactic acidosis
• Abstracts: Branched-chain amino acid-free parenteral nutrition in the treatment of acute metabolic decompensation in patients with maple syrup urine disease
• Abstracts: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
• Abstracts: Adapting the chronic disease model in the treatment of dually diagnosed patients. Organizational change required for paradigmatic shift in addiction treatment
• Abstracts: Primary care medicine in Canada. Recruitment, retention, and follow-up of graduates of a program to increase the number of family physicians in rural and underserved areas

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.